Cancer Screening for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
Do I need to stop my current medications to join the trial?
The trial does not specify if you need to stop taking your current medications. However, it mentions that women taking Tamoxifen or Evista/Raloxifene are allowed to participate, so it seems some medications may be permitted.
Is ultrasound imaging safe for humans?
Ultrasound imaging is generally considered safe for humans. A large study of over 23,000 cases using an ultrasound contrast agent found very few adverse events, with only two serious cases, indicating a good safety profile. Additionally, there is no evidence of harmful effects in fetuses, and safety measures are in place to ensure responsible use.12345
How is ultrasound imaging used in ovarian cancer screening different from other treatments?
Ultrasound imaging is unique in ovarian cancer screening because it helps detect changes in the ovaries' structure and blood flow, which can indicate cancer. Unlike other treatments, it is non-invasive and can identify early-stage cancers, although it is more effective in high-risk groups and often used alongside other tests like serum CA125.678910
What data supports the effectiveness of the treatment Ultrasonography for ovarian cancer screening?
Research shows that while ultrasound can detect early ovarian changes, large studies have not found it reduces death rates from ovarian cancer. Some trials, like the Kentucky trial, reported a shift to detecting cancer at earlier stages, which could improve survival, but overall, the benefit in reducing mortality is not clear.6781112
Who Is on the Research Team?
Christine D Berg
Principal Investigator
National Cancer Institute (NCI)
Are You a Good Fit for This Trial?
This trial is for older individuals who may be at risk of ovarian cancer, including germ cell tumors. Participants should be willing to undergo screening tests like biomarker analysis and ultrasound imaging, as well as fill out health questionnaires.Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Ovarian Screening
Participants undergo blood sample collection for CA125 analysis and transvaginal ultrasound (TVU) at baseline and annually for 3 years
Follow-up
Participants are monitored for cancer incidence and mortality through annual updates for at least 13 years
What Are the Treatments Tested in This Trial?
Interventions
- Ultrasonography
- Ultrasound Imaging
Ultrasonography is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor